M. Horiuchi

ORCID: 0009-0007-2666-9377
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Microtubule and mitosis dynamics
  • CNS Lymphoma Diagnosis and Treatment
  • Cellular Mechanics and Interactions
  • Cell Image Analysis Techniques
  • Chronic Lymphocytic Leukemia Research

Tokyo University of Pharmacy and Life Sciences
2024

Osaka City General Hospital
2019

The microtubule-associated protein MAP1B has been implicated in axonal growth and brain development. We found that is highly expressed the most aggressive deadliest breast cancer subtype, triple-negative (TNBC), but not other subtypes. Expression of was to be correlated with poor prognosis. Depletion TNBC cells impairs cell migration invasion concomitant a defect tumorigenesis. interacts key components for invadopodia formation, cortactin, Tks5, latter which PtdIns(3,4)P2-binding scaffold...

10.1083/jcb.202303102 article EN cc-by The Journal of Cell Biology 2024-02-14

Background: The immunoglobulin light chain restriction (iLCR) detected by flow cytometric analysis is useful to prove the monoclonality of B‐cell lymphoma. However, we occasionally encounter cases lymphoma without iLCR. lack expression on lymphomas arises from abnormalities gene transcription or translocation fully assembled proteins cell surface. Few reports have evaluated patients diffuse large (DLBCL) iLCR, but clinical characteristics and outcomes DLBCL lacking iLCR has not been firmly...

10.1097/01.hs9.0000565744.21637.de article EN cc-by-nc-nd HemaSphere 2019-06-01

Background: Treatment of patients with malignancy sometimes delay due to various reasons (e.g., additional examination, enrollment in clinical trial). Several studies revealed that an influence diagnosis‐to‐treatment interval (DTI) on outcomes differs depending the type malignancy. But, it is not well understood how delayed treatment affects diffuse large B‐cell lymphoma (DLBCL). Aims: In present study, we evaluated DTI and other parameters newly diagnosed DLBCL. Methods: We conducted a...

10.1097/01.hs9.0000559484.45214.5d article EN cc-by-nc-nd HemaSphere 2019-06-01
Coming Soon ...